Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis.

作者: Maciej Zerkowski , Mark D. Gustavson , Brian Bourke-Martin , Melissa Cregger , Jason Christiansen

DOI: 10.1043/1543-2165-133.9.1413

关键词:

摘要: Abstract Context.—There is critical need for standardization of HER2 immunohistochemistry testing in the clinical laboratory setting. Recently, American Society Clinical Oncology and College Pathologists have submitted guidelines recommending that laboratories achieve 95% concordance between assays observers testing. Objective.—As a potential aid to pathologists achieving these new guidelines, we conducted an examination using automated quantitative analysis (AQUA analysis) provide standardized expression score across instruments (sites), operators, staining runs. Design.—We analyzed by cohort (n = 669) invasive breast cancers tissue microarray format different 3), operators runs 3). Using light source, instrument calibration techniques, generation image software, produced normalized AQUA scores each ...

参考文章(27)
John M S Bartlett, Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. American Journal of Pharmacogenomics. ,vol. 5, pp. 303- 315 ,(2005) , 10.2165/00129785-200505050-00003
Jennet M. Harvey, Gary M. Clark, C. Kent Osborne, D. Craig Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 1474- 1474 ,(1999) , 10.1200/JCO.1999.17.5.1474
Christopher B. Moeder, Jennifer M. Giltnane, Malini Harigopal, Annette Molinaro, Andrew Robinson, Karen Gelmon, David Huntsman, Robert L. Camp, David L. Rimm, Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome Journal of Clinical Oncology. ,vol. 25, pp. 5418- 5425 ,(2007) , 10.1200/JCO.2007.12.8033
Robert L. Camp, Gina G. Chung, David L. Rimm, Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Medicine. ,vol. 8, pp. 1323- 1327 ,(2002) , 10.1038/NM791
Marisa Dolled-Filhart, Lisa Rydén, Melissa Cregger, Karin Jirström, Malini Harigopal, Robert L. Camp, David L. Rimm, Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays Clinical Cancer Research. ,vol. 12, pp. 6459- 6468 ,(2006) , 10.1158/1078-0432.CCR-06-1383
John E. Butler, Enzyme-Linked Immunosorbent Assay Journal of Immunoassay. ,vol. 21, pp. 165- 209 ,(2000) , 10.1080/01971520009349533
D E Raeside, Monte Carlo principles and applications Physics in Medicine and Biology. ,vol. 21, pp. 181- 197 ,(1976) , 10.1088/0031-9155/21/2/001
Aaron J. Berger, Darren W. Davis, Carmen Tellez, Victor G. Prieto, Jeffrey E. Gershenwald, Marcella M. Johnson, David L. Rimm, Menashe Bar-Eli, Automated Quantitative Analysis of Activator Protein-2α Subcellular Expression in Melanoma Tissue Microarrays Correlates with Survival Prediction Cancer Research. ,vol. 65, pp. 11185- 11192 ,(2005) , 10.1158/0008-5472.CAN-05-2300
Sharon Pozner-Moulis, Derek J. Pappas, David L. Rimm, Met, the Hepatocyte Growth Factor Receptor, Localizes to the Nucleus in Cells at Low Density Cancer Research. ,vol. 66, pp. 7976- 7982 ,(2006) , 10.1158/0008-5472.CAN-05-4335
Omar Hameed, Amy L. Adams, Allyson C. Baker, Nicole E. Balmer, Walter C. Bell, Holly N. Burford, David C. Chhieng, Nirag C. Jhala, Michael J. Klein, Thomas Winokur, Using a Higher Cutoff for the Percentage of HER2+ Cells Decreases Interobserver Variability in the Interpretation of HER2 Immunohistochemical Analysis American Journal of Clinical Pathology. ,vol. 130, pp. 425- 427 ,(2008) , 10.1309/KETM3HANLUQHW7YV